← All trials
NCT04592380
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2014
- Primary completion
- Feb 29, 2016
- Completion date
- Nov 30, 2016
- First posted
- Oct 19, 2020
- Last posted
- Oct 19, 2020
- Enrollment
- —
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- The Medicines CompanyLead sponsor
- Baylor UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.